Most recent guideline publication:
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020)
Updates since publication:
No updates on dosing recommendations since publication.
Tables provided in the main manuscript of the guideline:
| Table 1. Assignment of likely CYP2C9 phenotypes based on genotypes |
| Table 2. Therapeutic recommendations for celecoxib, flurbiprofen, lornoxicam and ibuprofen based on CYP2C9 phenotype |
| Table 3. Therapeutic recommendations for meloxicam based on CYP2C9 phenotype |
| Table 4. Therapeutic recommendations for piroxicam and tenoxicam based on CYP2C9 phenotype |
Supplement to: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020)
Tables and figures provided in the guideline publication supplement or referenced in the guidelinea:
| Supplemental Table S1. Evidence linking CYP2C9 genotype to celecoxib phenotype |
| Supplemental Table S2. Evidence linking CYP2C9 genotype to flurbiprofen phenotype |
| Supplemental Table S3. Evidence linking CYP2C9 genotype to lornoxicam phenotype |
| Supplemental Table S4. Evidence linking CYP2C9 genotype to ibuprofen phenotype |
| Supplemental Table S5. Evidence linking CYP2C9 genotype to meloxicam phenotype |
| Supplemental Table S6. Evidence linking CYP2C9 genotype to piroxicam phenotype |
| Supplemental Table S7. Evidence linking CYP2C9 genotype to tenoxicam phenotype |
| Supplemental Table S8. Evidence linking CYP2C9 genotype to NSAID phenotype |
| Supplemental Table S9. Evidence linking CYP2C9 genotype to aceclofenac, aspirin, diclofenac, indomethacin, lumiracoxib, metamizole, nabumetone and naproxen phenotype (No recommendation provided in guideline) |
| Supplemental Table S10. Evidence linking CYP2C8 genotype to ibuprofen and diclofenac phenotype (No recommendation provided in guideline) |
| Supplemental Table S11. Linkage disequilibrium between CYP2C9*2 and CYP2C8*3 across populations |
| Supplemental Table S12. Clinical pharmacokinetics of selected NSAIDs |
| Figure S2. Meta-analysis of the effect of CYP2C9 genotypes on celecoxib exposure |
| Figure S3. Meta-analysis of the effect of CYP2C9 genotypes on ibuprofen exposure |
| Figure S4. Meta-analysis of the effect of CYP2C9 genotypes on meloxicam exposure |
| CYP2C9 allele definition table |
| CYP2C9 allele functionality table |
| CYP2C9 frequency table |
| CYP2C9 diplotype-phenotype table |
| Gene resource mapping |
| Drug resource mapping |
| Clinical decision support:b
Celecoxib pre- and post-test alerts and flow chart Flurbiprofen pre- and post-test alerts and flow chart Lornoxicam pre- and post-test alerts and flow chart Ibuprofen pre- and post-test alerts and flow chart Meloxicam pre- and post-test alerts and flow chart |
aSome of the tables included in the guideline may have been updated on-line, particularly to reflect newly described or newly characterized alleles. These include the gene-specific information tables (https://www.pharmgkb.org/page/pgxGeneRef) that support CPIC guidelines by providing information regarding star (*) allele definitions, allele function, allele frequency by major ethnic groups, translations of diplotype to phenotype, and gene resource mappings.
bThese resources support the adoption of CPIC guidelines into the electronic health record with clinical decision support and provide information that clinical implementers find helpful.